Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

American Journal of Hematology

Volumn 86, Issue 3, 2011, Pages 251-255

  Kumar, Shaji K ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Hayman, Suzanne R ^a   Buadi, Francis K ^a   Zeldenrust, Steven R ^a   Tan, Tow ^a   Sinha, Shirshendu ^a   Leung, Nelson ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN; M PROTEIN; MELPHALAN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS; MALE; MELPHALAN; MIDDLE AGED; MYELOMA PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79951934818     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21948     Document Type: Article

References (30)

1. Kyle RA, Bayrd ED. "Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. Arch Intern Med 1961; 107: 344-353.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
3. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis. Best Pract Res Clin Haematol 2005; 18: 709-727.
4. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
5. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
6. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 2007; 92: 1415-1418.
7. Sanchorawala V, Seldin DC, Magnani B, et al. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transpl 2005; 36: 597-600.
8. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257-262.
9. van G, II, van Rijswijk MH, Bijzet J, et al. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009; 94: 1094-1100.
10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
11. Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274-278.
12. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
13. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113: 549-555.
14. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938.
15. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: Diagnosis and management. Clin Lymphoma Myeloma 2005; 6: 208-219.
16. Dispenzieri A, Merlini G, Comenzo RL. Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol Blood Marrow Transpl 2008; 14: 6-11.
17. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680.
18. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51: 878-881.
19. Akar H, Seldin DC, Magnani B, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005; 12: 210-215.
20. Bochtler T, Hegenbart U, Heiss C, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 2008; 93: 459-462.
21. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84.
22. Matsuda M, Yamada T, Gono T, et al. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 2005; 44: 428-433.
23. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378-3383.
24. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
25. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444.
26. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007; 110: 3561-3563.
27. Seldin DC, Anderson JJ, Skinner M, et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006; 108: 3945-3947.
28. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457-464.
29. Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295-298.
30. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-1037.